International Review of Psychiatry (Abingdon, England)最新文献_第7页

EEG biomarkers in major depressive disorder: discriminative power and prediction of treatment response. 重度抑郁障碍的脑电图生物标志物:鉴别能力和治疗反应的预测。

IF 2.8

International Review of Psychiatry (Abingdon, England) Pub Date : 2013-10-01 DOI: 10.3109/09540261.2013.816269

Sebastian Olbrich, Martijn Arns

{"title":"EEG biomarkers in major depressive disorder: discriminative power and prediction of treatment response.","authors":"Sebastian Olbrich, Martijn Arns","doi":"10.3109/09540261.2013.816269","DOIUrl":"https://doi.org/10.3109/09540261.2013.816269","url":null,"abstract":"Major depressive disorder (MDD) has high population prevalence and is associated with substantial impact on quality of life, not least due to an unsatisfactory time span of sometimes several weeks from initiation of treatment to clinical response. Therefore extensive research focused on the identification of cost-effective and widely available electroencephalogram (EEG)-based biomarkers that not only allow distinguishing between patients and healthy controls but also have predictive value for treatment response for a variety of treatments. In this comprehensive overview on EEG research on MDD, biomarkers that are either assessed at baseline or during the early course of treatment and are helpful in discriminating patients from healthy controls and assist in predicting treatment outcome are reviewed, covering recent decades up to now. Reviewed markers include quantitative EEG (QEEG) measures, connectivity measures, EEG vigilance-based measures, sleep-EEG-related measures and event-related potentials (ERPs). Further, the value and limitations of these different markers are discussed. Finally, the need for integrated models of brain function and the necessity for standardized procedures in EEG biomarker research are highlighted to enhance future research in this field.","PeriodicalId":306151,"journal":{"name":"International Review of Psychiatry (Abingdon, England)","volume":" ","pages":"604-18"},"PeriodicalIF":2.8,"publicationDate":"2013-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/09540261.2013.816269","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40260658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 251

The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy. 血液中药物和代谢物浓度作为精神药物治疗的生物标志物的价值。

IF 2.8

International Review of Psychiatry (Abingdon, England) Pub Date : 2013-10-01 DOI: 10.3109/09540261.2013.836475

Gudrun Hefner, A Kathrin Laib, Hilmar Sigurdsson, Matthias Hohner, Christoph Hiemke

{"title":"The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy.","authors":"Gudrun Hefner, A Kathrin Laib, Hilmar Sigurdsson, Matthias Hohner, Christoph Hiemke","doi":"10.3109/09540261.2013.836475","DOIUrl":"https://doi.org/10.3109/09540261.2013.836475","url":null,"abstract":"Desirable and undesirable effects of a drug are related to its concentration at various sites of actions. For many psychotropic drugs, it has been shown that drug concentration in brain correlates with concentration in blood. The latter is also an available estimate of clearance and bioavailability. Its monitoring enables identification of multiple factors that have an impact on clinical outcomes, especially uncertain compliance and pharmacokinetic peculiarities. For this review we analysed for antidepressants if drug concentration in blood can be used as biomarker for psychopharmacological treatment. Systematic review of the literature revealed for new and old antidepressant drugs that drug and metabolite concentrations in blood are measures of the pharmacokinetic phenotype and related differentially to occupancy of primary target structures, therapeutic effects and unwanted anticholinergic, cardiac and other side effects. Drug concentration in blood can therefore be used as biomarker in clinical practice to guide psychopharmacological treatment with established antidepressant drugs. Monitoring of drug concentration is suitable to improve efficacy and safety of the pharmacotherapy, especially in elderly patients who require complex pharmacological therapies.","PeriodicalId":306151,"journal":{"name":"International Review of Psychiatry (Abingdon, England)","volume":" ","pages":"494-508"},"PeriodicalIF":2.8,"publicationDate":"2013-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/09540261.2013.836475","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40260652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24

Future roles of pharmacogenomic testing and biomarkers in psychiatry. 药物基因组学检测和生物标志物在精神病学中的未来作用。

IF 2.8

International Review of Psychiatry (Abingdon, England) Pub Date : 2013-10-01 DOI: 10.3109/09540261.2013.845376

Daniel J Mueller, James L Kennedy, Hubertus Himmerich

{"title":"Future roles of pharmacogenomic testing and biomarkers in psychiatry.","authors":"Daniel J Mueller, James L Kennedy, Hubertus Himmerich","doi":"10.3109/09540261.2013.845376","DOIUrl":"https://doi.org/10.3109/09540261.2013.845376","url":null,"abstract":"Since the discovery of the antipsychotic action of chlorpromazine in 1952 (Delay et al., 1956), and of the antidepressant effect of imipramine in 1956 (Kuhn, 1957), the psychopharmacological portfolio has developed and differentiated substantially. Research has provided many insights into how molecular agents infl uence the dopamine, serotonin, noradrenalin, acetylcholine, and γ -aminobutyric acid neurotransmitter systems including their receptors, receptor subtypes, reuptake pumps and metabolizing enzymes. This has led to the development of several widely used medications. Additionally, medications have been developed to modulate the activity of neuronal ion channels providing further success in the exciting fi eld of neuropsychopharmacology. The fi eld will probably soon see the introduction of drugs infl uencing hormonal systems, cytokines, endogenous cannabinoids and eicosanoids as well as their second and third messengers. This undoubtedly will bring benefi ts to many more patients. However, despite those growing numbers of treatment options, substantial gaps in care remain due to limited of knowledge of how to match individual patients with individually appropriate drugs. As a result, only a small proportion of patients who receive ‘ adequate treatment ’ achieve full remission with the fi rst applied psychopharmacological drug (Himmerich","PeriodicalId":306151,"journal":{"name":"International Review of Psychiatry (Abingdon, England)","volume":" ","pages":"493"},"PeriodicalIF":2.8,"publicationDate":"2013-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/09540261.2013.845376","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40261261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Value of genetic and epigenetic testing as biomarkers of response to antidepressant treatment. 遗传和表观遗传检测作为抗抑郁治疗反应生物标志物的价值。

IF 2.8

International Review of Psychiatry (Abingdon, England) Pub Date : 2013-10-01 DOI: 10.3109/09540261.2013.816657

Helge Frieling, André Tadić

{"title":"Value of genetic and epigenetic testing as biomarkers of response to antidepressant treatment.","authors":"Helge Frieling, André Tadić","doi":"10.3109/09540261.2013.816657","DOIUrl":"https://doi.org/10.3109/09540261.2013.816657","url":null,"abstract":"Major depressive disorder (MDD) is one of the most prevalent and disabling psychiatric disorders worldwide and therefore an important public health priority. The selection process of antidepressant treatment is primarily guided by trial and error, and the outcomes with current antidepressant strategies are disappointing. The biological background of the disease is heterogeneous with presumably multiple biological systems involved. With the aim to individualize antidepressant treatment, multiple candidate gene and a few genome-wide association studies have been performed, but so far with very limited success. To address the dynamic changes of depressive symptoms and their response to treatment, recent studies focus on epigenetic mechanisms, as these are modulated by environmental stimuli and adaptive to different stages of the disorder. In the present paper, after a brief summary of the most important results from pharmacogenetic studies in MDD, we comment on the current and potential future value of genetic testing as a biomarker of response to antidepressant treatment. The new and exciting field of epigenetic mechanisms in antidepressant drug treatment will be presented in the second part of this review.","PeriodicalId":306151,"journal":{"name":"International Review of Psychiatry (Abingdon, England)","volume":" ","pages":"572-8"},"PeriodicalIF":2.8,"publicationDate":"2013-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/09540261.2013.816657","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40260655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Sleep as a biomarker for depression. 睡眠是抑郁症的生物标志物。

IF 2.8

International Review of Psychiatry (Abingdon, England) Pub Date : 2013-10-01 DOI: 10.3109/09540261.2013.812067

Adam Wichniak, Aleksandra Wierzbicka, Wojciech Jernajczyk

{"title":"Sleep as a biomarker for depression.","authors":"Adam Wichniak, Aleksandra Wierzbicka, Wojciech Jernajczyk","doi":"10.3109/09540261.2013.812067","DOIUrl":"https://doi.org/10.3109/09540261.2013.812067","url":null,"abstract":"Sleep is a complex biological process that involves cyclic changes of brain activity. The smooth transition between wakefulness and sleep and cyclic succession of sleep stages depend on the function of numerous neurotransmitters that reciprocally influence each other. For this reason sleep is a very sensitive biomarker of brain functioning. This article provides an overview of sleep changes in depression, mechanisms involved in sleep regulation and pathophysiology underlying depression, studies on sleep as a biomarker for depression, effects of antidepressants on sleep EEG, and studies in depression with the use of quantitative sleep EEG analysis. Research on sleep in depression has provided several valuable biomarkers that are related to increased risk for depression, show worsening during depressive episode, and are related to treatment outcome and relapse risk during remission phase. Among many sleep parameters, increased REM density and diminished delta sleep ratio deserve special interest. Sleep studies are also an important research tool for antidepressant drug development. However, due to sensitivity of sleep parameters to pharmacological interventions, the patients have to be investigated before the start of pharmacological treatment or after washout from the antidepressant drug, to obtain reliable data on disease-related biological processes from polysomnography.","PeriodicalId":306151,"journal":{"name":"International Review of Psychiatry (Abingdon, England)","volume":" ","pages":"632-45"},"PeriodicalIF":2.8,"publicationDate":"2013-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/09540261.2013.812067","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40260077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 78

Cytokines as biomarkers in depressive disorder: current standing and prospects. 细胞因子作为抑郁症的生物标志物:现状和前景。

IF 2.8

International Review of Psychiatry (Abingdon, England) Pub Date : 2013-10-01 DOI: 10.3109/09540261.2013.813442

Nicole Lichtblau, Frank M Schmidt, Robert Schumann, Kenneth C Kirkby, Hubertus Himmerich

{"title":"Cytokines as biomarkers in depressive disorder: current standing and prospects.","authors":"Nicole Lichtblau, Frank M Schmidt, Robert Schumann, Kenneth C Kirkby, Hubertus Himmerich","doi":"10.3109/09540261.2013.813442","DOIUrl":"https://doi.org/10.3109/09540261.2013.813442","url":null,"abstract":"The frequently observed co-occurrence of depressive disorders and inflammatory diseases suggests a close connection between the nervous and the immune systems. Increased pro-inflammatory and type 1 cytokines, such as interleukin (IL)-1, tumour necrosis factor (TNF)-α and interferon (IFN)-γ, appear to be an important link. Cytokines are synthesized by immune cells in the blood and peripheral tissues and by glial cells in the central nervous system (CNS). Evidence suggests that the blood-brain barrier (BBB) is permeable to cytokines and immune cells, and that afferent nerves, e.g. the vagus nerve, mediate the communication between peripheral inflammatory processes and CNS. Cytokines such as IL-1ß, TNF-α and IFN-γ seem to contribute to the pathophysiology of depression by activating monoamine reuptake, stimulating the hypothalamic-pituitary-adrenocortical (HPA) axis and decreasing production of serotonin due to increased activity of indolamine-2,3-dioxygenase (IDO). However, critical appraisal of these hypotheses is required, because cytokine elevation is not specific to depression. Moreover, several effective antidepressants such as amitriptyline and mirtazapine have been shown to increase cytokine production. When applying immunomodulatory therapies, these drugs may increase the risk of specific side effects such as infections or interact with antidepressant drugs on important functions of the body such as the coagulation system.","PeriodicalId":306151,"journal":{"name":"International Review of Psychiatry (Abingdon, England)","volume":" ","pages":"592-603"},"PeriodicalIF":2.8,"publicationDate":"2013-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/09540261.2013.813442","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40260657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 135

Gene expression: biomarker of antidepressant therapy? 基因表达:抗抑郁治疗的生物标志物?

IF 2.8

International Review of Psychiatry (Abingdon, England) Pub Date : 2013-10-01 DOI: 10.3109/09540261.2013.825580

Andreas Menke

{"title":"Gene expression: biomarker of antidepressant therapy?","authors":"Andreas Menke","doi":"10.3109/09540261.2013.825580","DOIUrl":"https://doi.org/10.3109/09540261.2013.825580","url":null,"abstract":"While antidepressant therapy is an essential treatment of major depression, a substantial group of treated patients do not respond to therapy, or suffer from severe side effects. Moreover, the time of onset of the clinical improvement is often delayed. Antidepressants as currently available usually enhance serotonergic, noradrenergic and dopaminergic neurotransmission and may contribute to the inadequate remission rates for major depression. Therefore biomarkers enabling the identification of subgroups of patients and also finding unprecedented targets would provide the basis for personalized medication and thus improve treatment efficacy and reduce side effects. Several pharmacogenetic studies on antidepressant treatment response using single nucleotide polymorphism (SNPs) mapping have been performed but provided only modest findings. Therefore the analysis of gene expression to integrate genomic activity and environmental effects promises a new approach to cope with the complexity of factors influencing antidepressant treatment. Here gene expression studies focusing on candidate genes and genome-wide approaches using RNA derived from peripheral blood cells are reviewed. The most promising findings exist for hypothalamic-pituitary-adrenal (HPA) axis, inflammation and neuroplasticity related genes. However, straightforward translation into tailored treatment is still unlikely. Contradictory results limit the clinical use of the findings. Future studies are necessary, which could include functional analysis and consider gene-environment interactions.","PeriodicalId":306151,"journal":{"name":"International Review of Psychiatry (Abingdon, England)","volume":" ","pages":"579-91"},"PeriodicalIF":2.8,"publicationDate":"2013-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/09540261.2013.825580","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40260656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 22

Neuroimaging as a potential biomarker to optimize psychiatric research and treatment. 神经影像学作为优化精神病学研究和治疗的潜在生物标志物。

IF 2.8

International Review of Psychiatry (Abingdon, England) Pub Date : 2013-10-01 DOI: 10.3109/09540261.2013.816659

Esther Walton, Jessica A Turner, Stefan Ehrlich

引用次数: 12

Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic. 在临床实践中实施CYP2D6和CYP2C19基因型:来自某药物遗传服务诊所的更新和报告。

IF 2.8

International Review of Psychiatry (Abingdon, England) Pub Date : 2013-10-01 DOI: 10.3109/09540261.2013.838944

Daniel J Müller, Ivana Kekin, Amy C C Kao, Eva J Brandl

{"title":"Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.","authors":"Daniel J Müller, Ivana Kekin, Amy C C Kao, Eva J Brandl","doi":"10.3109/09540261.2013.838944","DOIUrl":"https://doi.org/10.3109/09540261.2013.838944","url":null,"abstract":"Genetic testing may help to improve treatment outcomes in order to avoid non-response or severe side effects to psychotropic medication. Most robust data have been obtained for gene variants in CYP2D6 and CYP2C19 enzymes for antipsychotics and antidepressant treatment. We reviewed original articles indexed in PubMed from 2008-2013 on CYP2D6 and CYP2C19 gene variants and treatment outcome to antidepressant or antipsychotic medication. We have started providing CYP2D6 and CYP2C19 genotype information to physicians and conducted a survey where preliminary results are reported. Studies provided mixed results regarding the impact of CYP2D6 and CYP2C19 gene variation on treatment response. Plasma levels were mostly found associated with CYP metabolizer status. Higher occurrence/severity of side effects were reported in non-extensive CYP2D6 or CYP2C19 metabolizers. Results showed that providing genotypic information is feasible and generally well accepted by both patients and physicians. Although currently available studies are limited by small sample sizes and infrequent plasma drug level assessment, research to date indicates that CYP2D6 and CYP2C19 testing may be beneficial particularly for non-extensive metabolizing patients. In summary, clinical assessment of CYP2D6 and CYP2C19 metabolizer status is feasible, well accepted and optimizes drug treatment in psychiatry.","PeriodicalId":306151,"journal":{"name":"International Review of Psychiatry (Abingdon, England)","volume":" ","pages":"554-71"},"PeriodicalIF":2.8,"publicationDate":"2013-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/09540261.2013.838944","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40260654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 72

Review of somatic symptoms in post-traumatic stress disorder. 创伤后应激障碍的躯体症状综述

IF 2.8

International Review of Psychiatry (Abingdon, England) Pub Date : 2013-02-01 DOI: 10.3109/09540261.2012.736367

Madhulika A Gupta

{"title":"Review of somatic symptoms in post-traumatic stress disorder.","authors":"Madhulika A Gupta","doi":"10.3109/09540261.2012.736367","DOIUrl":"https://doi.org/10.3109/09540261.2012.736367","url":null,"abstract":"Post-traumatic stress disorder (PTSD) is associated with both (1) 'ill-defined' or 'medically unexplained' somatic syndromes, e.g. unexplained dizziness, tinnitus and blurry vision, and syndromes that can be classified as somatoform disorders (DSM-IV-TR); and (2) a range of medical conditions, with a preponderance of cardiovascular, respiratory, musculoskeletal, neurological, and gastrointestinal disorders, diabetes, chronic pain, sleep disorders and other immune-mediated disorders in various studies. Frequently reported medical co-morbidities with PTSD across various studies include cardiovascular disease, especially hypertension, and immune-mediated disorders. PTSD is associated with limbic instability and alterations in both the hypothalamic- pituitary-adrenal and sympatho-adrenal medullary axes, which affect neuroendocrine and immune functions, have central nervous system effects resulting in pseudo-neurological symptoms and disorders of sleep-wake regulation, and result in autonomic nervous system dysregulation. Hypervigilance, a central feature of PTSD, can lead to 'local sleep' or regional arousal states, when the patient is partially asleep and partially awake, and manifests as complex motor and/or verbal behaviours in a partially conscious state. The few studies of the effects of standard PTSD treatments (medications, CBT) on PTSD-associated somatic syndromes report a reduction in the severity of ill-defined and autonomically mediated somatic symptoms, self-reported physical health problems, and some chronic pain syndromes.","PeriodicalId":306151,"journal":{"name":"International Review of Psychiatry (Abingdon, England)","volume":" ","pages":"86-99"},"PeriodicalIF":2.8,"publicationDate":"2013-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/09540261.2012.736367","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31216392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 219